Title Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of This is on open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Address for correspondence: Jacqueline C. Barrientos, MD, CLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, 410 Lakeville Rd, Lake Success, NY 11042, jbarrientos@northwell.edu. Supplemental Data Supplemental data, figures, and tables accompanying this article can be found in the online version at https://doi.org/10.1016/j.clml. 2018.08.007. HHS Public Access Author manuscript Clin Lymphoma Myeloma Leuk. Author manuscript; available in PMC 2019 May 20. Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 December ; 18(12): 803–813.e7. doi:10.1016/j.clml.2018.08.007. A uhor M anscript